50 results on '"Chamié D"'
Search Results
2. 834 How Accurately can Physicians Predict Invasive Physiology Using Coronary Angiography? Results of an International Multi-Centre Survey
- Author
-
Nour, D., Shun-shin, M., Fung, M., Howard, J., Ahmed, Y., Allahwala, U., Alzuhairi, K., Bhindi, R., Chamie, D., Cook, C., Doi, S., Funayama, N., Hansen, P., Horinaka, R., Ishibashi, Y., Hijikata, N., Kaihara, T., Kawase, Y., Koga, M., Kotecha, T., Kuwata, S., Manica, A., Matsuo, H., Nakayama, M., Nijjer, S., Petraco, R., Rajkumar, C., Ramrakha, P., Ruparelia, N., Seligman, H., Sen, S., Takahashi, T., Tanabe, Y., Warisawa, T., Watanabe, A., Weaver, J., Yong, T., Francis, D., and Al-Lamee, R.
- Published
- 2020
- Full Text
- View/download PDF
3. DIRETRIZ DA SOCIEDADE BRASILEIRA DE CARDIOLOGIA E DA SOCIEDADE BRASILEIRA DE HEMODINÂMICA E CARDIOLOGIA INTERVENCIONISTA SOBRE INTERVENÇÃO CORONÁRIA PERCUTÂNEA
- Author
-
Feres, F, primary, Costa, RA, additional, Siqueira, D, additional, Costa Jr, JR, additional, Chamié, D, additional, Staico, R, additional, Chaves, AJ, additional, Abizaid, A, additional, Marin-Neto, JA, additional, Rassi Jr, A, additional, Botelho, R, additional, Alves, CMR, additional, Saad, JA, additional, Mangione, JA, additional, Lemos, PA, additional, Quadros, AS, additional, Queiroga, MAC, additional, Cantarelli, MJC, additional, and Figueira, HR, additional
- Published
- 2017
- Full Text
- View/download PDF
4. Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation.
- Author
-
Chamié D, Abizaid A, Costa JR Jr, Feres F, Almiro da Silva JF, Mattos LA, Staico R, Costa RA, Tanajura LF, Sousa AG, Sousa JE, Chamié, Daniel, Abizaid, Alexandre, Costa, J Ribamar Jr, Feres, Fausto, Almiro da Silva, J Fábio, Mattos, Luiz Alberto P, Staico, Rodolfo, Costa, Ricardo A, and Abizaid, Andréa
- Abstract
Despite the expressive reduction in the intimal hyperplasia (IH) formation after DES implantation at the mid-term, late restenosis has been recently noticed. Our objective was to determine, by means of serial angiography (QCA) and intravascular ultrasound (IVUS) at two different time points, whether the occurrence of the "late catch-up" phenomenon occurs after sirolimus-eluting stent (SES) implantation. Thirty-eight non-complex patients treated with a single 18-mm SES who had systematic serial QCA and IVUS analyses at mean 8 and 20 months were enrolled. Primary endpoint is to evaluate the temporal course of IH formation after SES implantation, by comparing QCA in-stent late loss and IVUS percent IH obstruction between the invasive follow-ups. Mean cohort age was 59.3 years and 31.6% were diabetics. Baseline reference vessel diameter was 2.8 ± 0.4 mm and lesion length was 11.5 ± 3.5 mm. Left anterior descending artery was the most frequent target vessel (55.3%). Between 8 and 20 months, a non-significant increase in in-stent late loss from 0.10 ± 0.18 to 0.15 ± 0.30 mm (P = 0.38) was observed. By IVUS, a slight increase in the percent IH obstruction (1.03 ± 2.13 to 1.76 ± 1.87%, P = 0.12) was detected between the two evaluations. Interestingly, all the neoformed tissue accrued from 8 to 20 months accumulated in the distal portion of the stent. In the non-complex scenario, SES implantation was associated with a minimal, non-significant increase in the IH volume between 8 and 20 months. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. Complete Revascularization in Acute Myocardial Infarction: The Clock Is Ticking.
- Author
-
Chamié D and Pfau S
- Subjects
- Humans, Treatment Outcome, Risk Factors, Clinical Decision-Making, Time Factors, Myocardial Infarction therapy, Myocardial Infarction physiopathology, Myocardial Infarction surgery, Percutaneous Coronary Intervention adverse effects
- Abstract
Competing Interests: Dr Chamié reports consulting fees from SpectraWave Medical and speaker fees from Boston Scientific. Dr Pfau reports no conflicts.
- Published
- 2024
- Full Text
- View/download PDF
6. Determining the Cause of Coronary Vasomotor Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries: Design and Rationale of the DISCOVER INOCA Prospective, Multicenter Registry.
- Author
-
Shah SM, Tremmel JA, Henry TD, Smilowitz NR, Prasad M, Kobayashi Y, Henry GA, Samady H, Samuels BA, Lerman A, Moses JW, Pietras C, Zhang Z, Tirziu D, Parise H, Cristea E, Chamié D, Grubman D, Henrici K, Matmusaeva E, Latif N, Cigarroa N, and Lansky AJ
- Abstract
Background: Approximately 30% to 50% of patients who are referred for diagnostic coronary angiography are found to have no obstructive coronary artery disease (CAD). Ischemia and nonobstructive coronary arteries (INOCA) is increasingly recognized and encompasses coronary microvascular dysfunction, vasospastic angina, symptomatic myocardial bridging, and other vasomotor disorders. However, the prevalence of these disorders and whether underlying atherosclerotic plaque burden and morphology affect the long-term outcomes of each physiologic phenotype is unknown., Methods: The DISCOVER INOCA registry is ongoing at 8 centers in the United States and plans to enroll 500 patients with ischemic heart disease referred for angiography undergoing coronary function testing (CFT). All participants will complete patient-reported outcome measures and undergo protocol-guided angiography, acetylcholine provocation, coronary thermodilution, and intravascular imaging. Follow-up assessments occur at 30 days, 6 months, 1 year, and annually for 5 years. The primary short-term end point is the prevalence of INOCA phenotypes based on physiology and the degree of atherosclerosis based on intravascular ultrasound or optical coherence tomography (intravascular imaging). The primary long-term end point is the incidence of major adverse cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, hospitalization for cardiovascular causes, or coronary revascularization at a follow-up of 5 years. At the time of this publication, 100 participants have been enrolled., Conclusions: DISCOVER INOCA is the first prospective study of INOCA patients to integrate anatomic and physiologic measures of disease and correlate them with long-term outcomes. DISCOVER INOCA will report on the prevalence of INOCA phenotypes, the safety of comprehensive invasive CFT, and the impact of testing on diagnoses and medical therapy. Symptoms and cardiovascular adverse events at long-term follow-up will be determined in patients with no obstructive CAD undergoing angiography., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
7. First-in-Human Experience With a Novel Multimodality DeepOCT-NIRS Intracoronary Imaging System.
- Author
-
Ali ZA, Dager A, Zúñiga M, Fonseca J, Arana C, Chamié D, Hill JM, Madder RD, Muller JE, Simonton CA, Tearney GJ, and Stone GW
- Published
- 2024
- Full Text
- View/download PDF
8. Final 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data.
- Author
-
Verheye S, Vrolix M, Montorfano M, Giannini F, Bedogni F, Dubois C, De Bruyne B, Costa RA, Chamié D, Costa JR Jr, Abizaid A, and Colombo A
- Abstract
Background: The DynamX Novolimus-Eluting Coronary Bioadaptor System ( DynamX ® Bioadaptor) has uncaging elements that disengage after the resorption of the polymer coating, aiming to restore vessel function in the treated segment and to avoid long-term adverse outcomes associated with the permanent caging of the coronary artery seen with conventional stenting., Methods: This prospective, multicenter, single-arm first-in-human study enrolled 50 patients in Belgium and Italy who were treated with the DynamX Bioadaptor. Eligible patients had de novo lesions in coronary arteries measuring between 2.5 and 3.5 mm in diameter and ≤ 24 mm in length. Clinical follow-up was performed up to 36 months. This analysis includes the intention-to-treat population and is based on data available. The preclinical studies include optical coherence tomography (OCT) analyses of 5 DynamX Bioadaptors implanted in 3 mini Yucatan pigs (at 3, 12 and 24 months), and assessment of smooth muscle cell gene expression profile in 8 pigs of which each was implanted with the DynamX Bioadaptor and the Xience drug-eluting stent. To assess the gene expression profile by quantitative real-time polymerase chain reaction, animals were sacrificed at 3, 6, 9 and 12 months., Results: Target lesion failure at 36 months was 8.7% (4/46), consisting of one clinically-driven target lesion revascularization and 3 cardiac deaths (all site-reported to be unrelated to the device or procedure). There were no additional target vessel revascularization and no definite or probable scaffold thrombosis. Preclinical data confirmed late lumen enlargement (from 7.02 ± 1.31 mm 2 at baseline to 8.46 ± 1.31 mm 2 at 24 months) and identified an increased expression of contractile genes around 9 months compared to a conventional drug-eluting stent., Conclusions: The DynamX Bioadaptor demonstrated very good 36-month clinical outcomes, highlighted by the absence of target-vessel myocardial infarction and definite or probable device thrombosis, and only one target lesion revascularization up to 36 months. These data are supported by preclinical studies that showed late lumen enlargement by OCT and an increased expression of contractile genes around 9 months compared to conventional drug-eluting stents, indicating faster vessel healing. Larger clinical studies are necessary to compare outcomes against contemporary drug-eluting stents., Clinical Trial Registration: https://clinicaltrials.gov/: NCT03429894., Competing Interests: The institutions of SV, MV, MM, FG, FB, CD, BDB, AC received research funding from Elixir Medical to conduct the study, RAC, DC, JRC and AA were involved in the core laboratory. SV reports consultancy fees from Neovasc outside the submitted work and speaker fees from Elixir Medical. BdB reports consulting fees from Abbott Vascular, Boston Scientific, Medyrial, and Xenter paid to his institution. AC reports honoraria for lectures/presentations. The other authors declare no conflict of interest., (Copyright: © 2023 The Author(s). Published by IMR Press.)
- Published
- 2023
- Full Text
- View/download PDF
9. Ioxaglate Versus IoDixanol for the Prevention of Contrast-Induced Nephropathy: The IDPC Trial.
- Author
-
Freitas RAP, Tanajura LF, Mehran R, Chamié D, Chaves A, Centemero M, Braga S, Costa R, Cao D, Sousa A, Feres F, and Costa JR Jr
- Subjects
- Aged, Humans, Contrast Media adverse effects, Coronary Angiography adverse effects, Coronary Angiography methods, Creatinine, Risk Factors, Triiodobenzoic Acids adverse effects, Ioxaglic Acid adverse effects, Kidney Diseases chemically induced
- Abstract
Background: Despite the potential benefits of percutaneous procedures for the assessment and treatment of coronary artery disease, these interventions require the use of iodine contrast, which might lead to contrast-induced nephropathy (CIN) and increased risk of dialysis and major adverse cardiac events (MACE)., Aims: We sought to compare two different iodine contrasts (low vs. iso-osmolar) for the prevention of CIN among high-risk patients., Methods: This is a single-center, randomized (1:1) trial comparing consecutive patients at high risk for CIN referred to percutaneous coronary diagnostic and/or therapeutic procedures with low (ioxaglate) vs. iso-osmolarity (iodixanol) iodine contrast. High risk was defined by the presence of at least one of the following conditions: age >70 years, diabetes mellitus, non-dialytic chronic kidney disease, chronic heart failure, cardiogenic shock, and acute coronary syndrome (ACS). The primary endpoint was the occurrence of CIN, defined as a >25% relative increase and/or >0.5 mg/dL absolute increase in creatinine (Cr) levels compared with baseline between the 2nd and 5th day after contrast media administration., Results: A total of 2,268 patients were enrolled. Mean age was 67 years. Diabetes mellitus (53%), non-dialytic chronic kidney disease (31%), and ACS (39%) were highly prevalent. The mean volume of contrast media was 89 ml ± 48.6. CIN occurred in 15% of all patients, with no significant difference regarding the type of contrast used (iso = 15.2% vs. low = 15.1%, P>.99). Differences were not observed in specific subgroups such as diabetics, elderly, and ACS patients. At 30-day follow-up, 13 patients in the iso-osmolarity group and 11 in low-osmolarity group required dialysis (P =.8). There were 37 (3.3%) deaths in the iso-osmolarity cohort vs. 29 (2.6%) in the low-osmolarity group (P =.4)., Conclusion: Among patients at high risk for CIN, the incidence of this complication was 15%, and independent of the use of low- or iso-osmolar contrast.
- Published
- 2023
- Full Text
- View/download PDF
10. Serial Assessment of Coronary Artery Healing of a Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months by Optical Coherence Tomography (OCT)-The REPAIR Trial.
- Author
-
Silva GBG, Meneguz-Moreno RA, Costa R, Chamié D, Dangas G, Manica A, Arruda JA, Sousa AGMR, Feres F, and Costa JR Jr
- Subjects
- Humans, Male, Middle Aged, Female, Tomography, Optical Coherence methods, Prospective Studies, Treatment Outcome, Prosthesis Design, Stents, Polymers, Coronary Artery Disease therapy, Drug-Eluting Stents, Diabetes Mellitus, Type 2
- Abstract
Background: Although first-generation drug-eluting stent (DES) devices have effectively achieved their main goal of reducing restenosis, their safety has been limited by suboptimal polymer biocompatibility, delayed stent endothelialization, and local drug toxicity, which ultimately prompted the development of new-generation DES options carrying biocompatible or even biodegradable polymers., Aims: We sought to assess the vessel-healing pattern of the novel sirolimus-eluting Inspiron DES (Scitech Medical) using serial optical coherence tomography (OCT) and assuming the hypothesis that this thin-strut (75-μm), biodegradable-polymer DES promotes a faster healing, with very early strut coverage., Methods: This is a prospective, multicenter, open-label, single-arm study enrolling 68 patients who underwent percutaneous coronary intervention guided by OCT. These patients were consecutively assigned into 3 groups. The first group had its OCT imaging follow-up performed at 3 months, the second group at 2 months, and the third group at 1 month., Results: Mean age was 59.5 years, 70.6% were male, 41.2% had type 2 diabetes, and 29.4% presented with acute coronary syndrome. A total of 72 lesions were treated and 1.06 stents were implanted per patient. OCT assessment of the stents at 1, 2, and 3 months showed a strut coverage of 90.41%, 93.96%, and 97.21%, respectively (P=.04)., Conclusion: The Inspiron DES showed an early strut healing pattern, with >90% of the struts covered by neointima within the first month and with almost all struts covered by the third month.
- Published
- 2023
- Full Text
- View/download PDF
11. Sinus of Valsalva Pseudoaneurysm: An Unusual Cause of Complete Heart Block.
- Author
-
Centemero M, Urdanetta LR, Maschiarelli I, Barreto R, Mendez CA, Delamain JH, Wolf PW, Terrível D, Feres F, and Chamié D
- Abstract
We present a case of a young man with complete atrioventricular block and aneurysm of the right sinus of Valsalva penetrating the interventricular septum and causing severe aortic regurgitation. Chest trauma and inflammatory or infectious diseases are potential causes. Bentall-de Bono surgical repair was performed. Anatomopathologic analysis demonstrated fibrosis, hyalinization, and extensive myxoid material. ( Level of Difficulty: Beginner. )., Competing Interests: The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
12. Intravascular Imaging for Percutaneous Coronary Intervention Guidance and Optimization: The Evidence for Improved Patient Outcomes.
- Author
-
Mintz GS, Bourantas CV, and Chamié D
- Abstract
As of this writing, there have been approximately 24 randomized controlled trial publications, 32 meta-analyses, and 85 registries comparing intravascular ultrasound (IVUS) or optical coherence tomography (OCT) versus angiography-guided drug-eluting stent implantation (or IVUS versus OCT guidance). Although in specific clinical scenarios IVUS or OCT may be preferred, in most drug-eluting stent implantation procedures, either intravascular ultrasound or OCT can be used safely, efficiently, effectively, and interchangeably and will improve patient outcomes compared with stent implantation procedures performed just with angiography guidance., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
13. Healing and early stent coverage after ultrathin strut biodegradable polymer-coated sirolimus-eluting stent implantation: SiBi optical coherence tomography study.
- Author
-
Abhyankar A, Abizaid A, Chamié D, and Patel G
- Subjects
- Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Humans, Neointima, Pilot Projects, Polymers, Sirolimus, Stents, Tomography, Optical Coherence, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Drug-Eluting Stents, Percutaneous Coronary Intervention
- Abstract
Aims: The aim of SiBi study was to evaluate the early vascular healing and neointimal coverage after implantation of ultrathin (60 μm) biodegradable polymer-coated Tetriflex (Sahajanand Medical Technologies Pvt. Ltd., Surat, India) sirolimus-eluting stent (SES) using optical coherence tomography (OCT) at 4 to 6 weeks after implantation., Methods: SiBi was a single-center, observational, investigator-initiated study. From January 15, 2018 to April 15, 2018, total 29 consecutive patients who had consented and underwent OCT examination at 4-6 weeks after Tetriflex SES implantation were enrolled. All OCT images were analyzed at an independent core laboratory by analysts who were blinded to patient and procedural information., Results: Of 29 patients, four patients were excluded, as those OCT images were technically inadequate for analysis. Therefore, 25 patients were included in final OCT analysis. Average OCT analysis was performed after 35.3 ± 5 days of Tetriflex implantation. Total 14,024 stent struts in 1,520 cross sections were analyzed. Strut tissue coverage was observed in 91.26 ± 5.53% of struts and malapposed struts were seen in 0.89 ± 1.67%. The mean neointimal hyperplasia (NIH) thickness on the covered struts was 50 ± 30 μm., Conclusion: A large percentage of struts were found to be covered with thin layer of NIH evenly distributed along the stent length at around 1 month from stent implantation. The results of this pilot study serve as ethical and scientific backbone to conduct an adequately powered clinical trial to evaluate outcomes of short dual-antiplatelet therapy in context of ultrathin strut stent., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
14. Response by Chamié et al to Letter Regarding Article, "Optical Coherence Tomography Versus Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary Interventions: The iSIGHT Randomized Trial".
- Author
-
Chamié D, Petraco R, and Feres F
- Subjects
- Coronary Angiography, Humans, Ultrasonography, Interventional, Percutaneous Coronary Intervention adverse effects, Tomography, Optical Coherence
- Published
- 2021
- Full Text
- View/download PDF
15. Stent type identification with optical coherence tomography: novelty in search of clinical application.
- Author
-
Chamié D and Petraco R
- Subjects
- Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Humans, Stents, Tomography, Optical Coherence, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Drug-Eluting Stents, Percutaneous Coronary Intervention
- Published
- 2021
- Full Text
- View/download PDF
16. Optical Coherence Tomography Versus Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary Interventions: The iSIGHT Randomized Trial.
- Author
-
Chamié D, Costa JR Jr, Damiani LP, Siqueira D, Braga S, Costa R, Seligman H, Brito F, Barreto G, Staico R, Feres F, Petraco R, and Abizaid A
- Subjects
- Coronary Angiography, Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Humans, Tomography, Optical Coherence, Treatment Outcome, Ultrasonography, Interventional, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Percutaneous Coronary Intervention adverse effects
- Abstract
[Figure: see text].
- Published
- 2021
- Full Text
- View/download PDF
17. Comparison of neointimal coverage between ultrathin biodegradable polymer-coated sirolimus-eluting stents and durable polymer-coated everolimus-eluting stents: 6 months optical coherence tomography follow-up from the TAXCO study.
- Author
-
Abhyankar A, Abizaid A, Chamié D, and Rathod M
- Subjects
- Absorbable Implants, Animals, Everolimus, Follow-Up Studies, Humans, Neointima, Polymers, Sirolimus, Stents, Tomography, Optical Coherence, Treatment Outcome, Drug-Eluting Stents, Odonata, Percutaneous Coronary Intervention adverse effects
- Abstract
Aim: The TAXCO study was designed to compare the degree of neointimal coverage and the prevalence of malapposition at 6 months subsequent to implantation of ultrathin biodegradable polymer-coated sirolimus-eluting stents (SES) and durable polymer-coated everolimus-eluting stents (EES) of thin strut thickness using optical coherence tomography (OCT)., Methods: The TAXCO study included a total of 42 patients who gave consent and underwent OCT examination between August 2017 and September 2017. Of 42, five patients' OCT examinations were of insufficient quality for quantitative analysis. Thus, the OCT analysis group consisted of 37 patients. Among them, 16 patients were treated with Xience (Abbott Vascular) and 21 with Tetriflex (Sahajanand Medical Technologies Pvt. Ltd., Surat, India), 6 (±1) months earlier at our institution. The OCT was performed using a C7 Dragonfly™ imaging catheter (St. Jude Medical Inc.). All OCT images were analyzed at an independent core laboratory (Cardiovascular Research Center, São Paulo, Brazil) by analysts who were blinded to patient and procedural information., Results: A total of 763 crosssections (6,882 struts) were analyzed in Xience group, and 1,127 crosssections (9,968 struts) in Tetriflex group. At 6 months, on per-lesion basis, no significant differences were observed between Xience group and Tetriflex group in mean percentage of uncovered struts (1.87 ± 3.86 vs. 2.42 ± 3.46, p = .137) and malapposed struts (0.05 ± 0.2 vs. 0.21 ± 0.69, p = .302). Strut-level neointimal thickness also did not differ between Xience group and Tetriflex group (0.18 ± 0.12 vs. 0.14 ± 0.08 mm, p = .286)., Conclusion: This OCT study found no significant difference in strut coverage and neointimal thickness at 6 months after implantation of biodegradable polymer-coated Tetriflex, when compared with durable polymer-coated Xience., (© 2020 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
18. Twelve-month clinical and imaging outcomes of the uncaging coronary DynamX bioadaptor system.
- Author
-
Verheye S, Vrolix M, Montorfano M, Zivelonghi C, Giannini F, Bedogni F, Dubois C, De Bruyne B, Costa RA, Chamié D, de Ribamar Costa J Jr, Kereiakes DJ, Abizaid AA, and Colombo A
- Subjects
- Coronary Angiography, Humans, Sirolimus, Tomography, Optical Coherence, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Drug-Eluting Stents, Percutaneous Coronary Intervention adverse effects
- Abstract
Aims: We aimed to assess the safety and efficacy of the DynamX Novolimus-Eluting Coronary Bioadaptor System, a novel device that initially acts as a second-generation drug-eluting stent, but after six months frees the vessel through uncaging elements., Methods and Results: This multicentre study enrolled 50 patients with single de novo lesions. In-device acute lumen gain was 1.61±0.34 mm, and device and procedure success was 100%. Up to 12 months, two target lesion failures occurred: both were cardiac deaths (day 255 and day 267 post procedure). No definite or probable device thrombosis was observed. Mean late lumen loss was 0.12±0.18 mm in-device and 0.11±0.16 mm in-segment. Per intravascular ultrasound, the mean device area and mean vessel area increased significantly by 5% and 3%, respectively, while the mean lumen area was maintained. Stationary optical coherence tomography in seven patients demonstrated restoration of cyclic pulsatility, with an approximate lumen area variance of 11% between systole and diastole., Conclusions: The DynamX bioadaptor showed drug-eluting stent-like acute performance and safety and efficacy up to one year. Positive remodelling with an increase of vessel and device area while maintaining the mean lumen area was demonstrated. Long-term follow-up and randomised trials are required to assess the benefit of this device on events beyond one year.
- Published
- 2020
- Full Text
- View/download PDF
19. Adapted Catheterization Laboratory Practices during the COVID-19 Pandemic: The Instituto Dante Pazzanese de Cardiologia Protocol.
- Author
-
Chamié D, Oliveira F, Braga S, Costa JR, Siqueira DAA, Staico R, Costa R, Maldonado G, Tanajura LFL, Centemero MP, Chaves ÁJ, Abizaid ACSL, Freitas RAP, Coelho NT, Ohe LN, Abboud C, and Feres F
- Subjects
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2, Cardiology methods, Catheterization methods, Coronavirus Infections epidemiology, Pneumonia, Viral epidemiology
- Published
- 2020
- Full Text
- View/download PDF
20. Diagnostic Accuracy of 320-Row Computed Tomography for Characterizing Coronary Atherosclerotic Plaques: Comparison with Intravascular Optical Coherence Tomography.
- Author
-
Ybarra LF, Szarf G, Ishikawa W, Chamié D, Caixeta A, Puri R, and Perin MA
- Subjects
- Aged, Cholesterol analysis, Coronary Artery Disease metabolism, Coronary Artery Disease pathology, Coronary Vessels chemistry, Coronary Vessels pathology, Crystallization, Female, Fibrosis, Humans, Macrophages pathology, Male, Middle Aged, Neovascularization, Pathologic, Predictive Value of Tests, Prognosis, Registries, Reproducibility of Results, Retrospective Studies, Vascular Calcification metabolism, Vascular Calcification pathology, Computed Tomography Angiography, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Vessels diagnostic imaging, Multidetector Computed Tomography, Plaque, Atherosclerotic, Tomography, Optical Coherence, Vascular Calcification diagnostic imaging
- Abstract
Background/purpose: This study sought to determine the diagnostic accuracy of 320-row computed tomography (320CT) for characterizing coronary atherosclerotic plaques in comparison with optical coherence tomography (OCT)., Methods/materials: From 32 patients, 42 coronary segments were evaluated and co-registered by both 320CT and OCT. 320CT vulnerable plaque characteristics included low attenuation plaque (LAP) (<30HU), napkin-ring sign (NRS), positive remodeling (PR) and spotty calcification (SC). The presence of macrophage, neovascularization and cholesterol crystals was also determined by OCT., Results: Minimal lumen area was 2.78 ± 1.23 mm by OCT and 3.29 ± 1.49 mm by 320CT (p < 0.001). Noncalcified plaques were classified accordingly by both methods in 88.2% of the cases (p = 0.005). There was no association between any 320CT plaque type and OCT fibroatheroma (p = 0.62). The combination of 2 or more of the 320CT vulnerable plaque characteristics was associated with the presence of macrophage (74.2 vs. 25.8%; p = 0.034) and cholesterol crystals (85.7 vs. 14.3%; p = 0.04), but not with neovascularization (p = 0.65). The presence of all four characteristics demonstrated an accuracy of 75.1% for detecting OCT fibroatheroma., Conclusions: 320CT is useful for non-invasive evaluation of calcified and noncalcified tissue characteristics of coronary atheroma. The combination of all four 320CT vulnerable plaque characteristics provided the highest accuracy for detecting fibroatheromas., Summary: 320CT is useful for non-invasive evaluation of calcified and noncalcified tissue characteristics of coronary atheroma. The combination of all 320CT vulnerable plaque characteristics (low attenuation plaque (<30HU), napkin-ring sign, positive remodeling and spotty calcification) provided the highest accuracy for detecting fibroatheromas compared to optical coherence tomography., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
21. Invasive Physiological Assessment: From Binary to Continuous.
- Author
-
Chamié D and Abizaid A
- Subjects
- Catheterization, Humans, Longitudinal Studies, Pilot Projects, Models, Statistical, Myocardial Ischemia
- Published
- 2020
- Full Text
- View/download PDF
22. Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions.
- Author
-
Verheye S, Costa RA, Schofer J, Ormiston JA, Maeng M, Dudek D, Skurk C, Botelho RV, Costa JR, Chamié D, Abizaid AS, Boersma E, and Abizaid AA
- Subjects
- Coronary Stenosis surgery, Humans, Treatment Outcome, Absorbable Implants, Biocompatible Materials therapeutic use, Coronary Artery Disease therapy, Coronary Stenosis drug therapy, Drug-Eluting Stents, Immunosuppressive Agents therapeutic use, Macrolides therapeutic use, Percutaneous Coronary Intervention
- Published
- 2019
- Full Text
- View/download PDF
23. Imaging-guided pre-dilatation, stenting, post-dilatation: a protocolized approach highlighting the importance of intravascular imaging for implantation of bioresorbable scaffolds.
- Author
-
Ali ZA, Karimi Galougahi K, Shlofmitz R, Maehara A, Mintz GS, Abizaid A, Chamié D, Hill J, Serruys PW, Onuma Y, and Stone GW
- Subjects
- Coronary Artery Disease therapy, Dilatation, Drug-Eluting Stents, Humans, Hyperplasia, Neointima pathology, Prosthesis Design, Tissue Scaffolds, Treatment Outcome, Absorbable Implants, Percutaneous Coronary Intervention methods, Stents
- Abstract
Introduction: The advent of the fully bioresorbable vascular scaffold (BVS) is the latest step in a series of advancements in the design of intracoronary stents over the past few decades. The novelty of this technology is in providing temporary vessel scaffolding and local antiproliferative therapy to prevent neointimal hyperplasia after percutaneous coronary intervention followed by gradual resorption of the scaffold to restore the native vessel anatomy and physiology - a process termed vascular reparative therapy. Areas covered: The first generation of BVS has not been able to fully match the high benchmark in safety and efficacy set by contemporary metallic drug-eluting stents. These shortcomings of BVS may be due to factors related to the device itself, the complexity of the underlying lesion, or the implantation technique. Expert commentary: Here, how intravascular imaging may be used to minimize these shortcomings is described and moreover, an imaging-guided step-by-step approach for BVS implantation that integrates the recently described pre-dilatation, stenting, post-dilatation (PSP) strategy is explained.
- Published
- 2018
- Full Text
- View/download PDF
24. Suboptimal Bifurcation Stenting: A Case When the Check Comes Late.
- Author
-
Zukowski C, Maia F, Oliveira M, Mattos LA, Pontes A, Costa RA, and Chamié D
- Subjects
- Aged, Coronary Angiography, Coronary Artery Disease complications, Coronary Artery Disease diagnostic imaging, Humans, Male, Predictive Value of Tests, Risk Factors, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction surgery, Time Factors, Tomography, Optical Coherence, Treatment Failure, Coronary Artery Disease surgery, Drug-Eluting Stents, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention instrumentation, ST Elevation Myocardial Infarction etiology
- Published
- 2018
- Full Text
- View/download PDF
25. CKD-EPI versus Cockcroft-Gault formula for predicting contrast-induced nephropathy following percutaneous coronary intervention in patients without significant renal impairment.
- Author
-
Nunes MBG, Filho AC, Alvares VRC, Meneguz-Moreno R, Lamas E, Loures V, Chamié D, and Abizaid A
- Subjects
- Contrast Media, Cross-Sectional Studies, Glomerular Filtration Rate, Humans, Male, Percutaneous Coronary Intervention, Renal Insufficiency, Chronic
- Abstract
Introduction: Individuals with glomerular filtration rate (GFR) ≥60 ml/min/1.73 m
2 estimated by the Cockcroft-Gault formula (CG) who undergo percutaneous coronary intervention (PCI) frequently develop contrast-induced nephropathy (CIN). This study aimed to assess whether individuals with significant renal impairment assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, but not by CG, more often develop CIN following PCI than those without renal impairment by either formula., Methods: In this cross-sectional study analyzing patients with baseline CG GFR ≥60 ml/min/1.73 m2 before PCI, subjects were divided into two groups according to CIN occurrence. Baseline CKD-EPI GFR was calculated for all patients., Results: We analyzed 140 patients. Baseline GFR was 87.5±21.3 and 77.1±15.0 ml/min/1.73 m2 for CG and CKD-EPI, respectively. CIN occurred in 84.6% of individuals with baseline CKD-EPI GFR <60 ml/min/1.73 m2 vs. 51.1% of those without. Males and those with higher body mass index were more likely to present baseline CKD-EPI GFR <60 ml/min/1.73 m2 (p=0.021). Non-ionic contrast agent use and baseline CKD-EPI GFR ≥60 ml/min/1.73 m2 were protective factors against CIN. Greater amounts of contrast agent and acute coronary syndrome were associated with higher CIN risk. In subjects with serum creatinine <1.0 mg/dl, GFR was more likely to be overestimated by CG, but not by CKD-EPI (sensitivity 100.0%; specificity 52.0%)., Conclusion: In patients undergoing PCI without renal dysfunction by CG, a finding of CKD-EPI GFR <60 ml/ min/1.73 m2 was associated with a higher probability of CIN, especially among men and those with higher body mass index., (Copyright © 2017 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
26. Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months).
- Author
-
Chevalier B, Smits PC, Carrié D, Mehilli J, Van Boven AJ, Regar E, Sawaya FJ, Chamié D, Kraaijeveld AO, Hovasse T, and Vlachojannis GJ
- Subjects
- Aged, Cardiovascular Agents adverse effects, Coronary Artery Disease diagnostic imaging, Coronary Vessels diagnostic imaging, Europe, Female, Humans, Hyperplasia, Male, Middle Aged, Neointima, Percutaneous Coronary Intervention adverse effects, Predictive Value of Tests, Prospective Studies, Prosthesis Design, Risk Factors, Sirolimus adverse effects, Time Factors, Treatment Outcome, Wound Healing drug effects, Absorbable Implants, Cardiovascular Agents administration & dosage, Coronary Artery Disease therapy, Coronary Vessels drug effects, Drug-Eluting Stents, Percutaneous Coronary Intervention instrumentation, Polyesters chemistry, Sirolimus administration & dosage, Tomography, Optical Coherence
- Abstract
Background: To assess the vessel-healing pattern of Ultimaster drug-eluting stent using optical frequency domain imaging. Our hypothesis is that biodegradable polymer-based drug-eluting technology allows complete very early strut coverage., Methods and Results: The DISCOVERY 1TO3 study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months) is a prospective, single-arm, multicenter study. A total of 60 patients with multivessel disease requiring staged procedure at 1 month were treated with Ultimaster. Optical frequency domain imaging was acquired at baseline, 1, 2, and 3 months. The primary end point is optical frequency domain imaging-assessed strut coverage at 3 months. Mean age of patients was 67.2±9.9 years, and 73.3% were male, and 36.7% presented with acute coronary syndrome. A total of 132 lesions were treated, with average 1.4 lesions per patient treated at baseline and 1.1 lesions treated at 1 month. Strut coverage at 3 months of single implanted stents (n=71, primary end point) was 95.2±5.2% and of combined single and overlapped stents was 95.4±4.9%. Strut coverage of combined single and overlapped stents at 1 (n=49) and 2 months (n=38) was 85.1±12.7% and 87.9±10.8%, respectively. The median neointimal hyperplasia thickness was 0.04, 0.05, and 0.06 mm, whereas mean neointimal hyperplasia obstruction was 4.5±2.4%, 5.2±3.4%, and 6.6±3.3% at 1, 2, and 3 months, respectively., Conclusions: Nearly complete strut coverage was observed in this complex population very early after implantation of Ultimaster drug-eluting stent., Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01844843., (© 2017 American Heart Association, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
27. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
- Author
-
Tenekecioglu E, Serruys PW, Onuma Y, Costa R, Chamié D, Sotomi Y, Yu TB, Abizaid A, Liew HB, and Santoso T
- Subjects
- Cardiovascular Agents adverse effects, Coronary Restenosis diagnostic imaging, Coronary Restenosis etiology, Coronary Stenosis diagnostic imaging, Female, Humans, Indonesia, Malaysia, Male, Middle Aged, Percutaneous Coronary Intervention adverse effects, Predictive Value of Tests, Prospective Studies, Prosthesis Design, Risk Factors, Single-Blind Method, Sirolimus adverse effects, Time Factors, Treatment Outcome, Absorbable Implants, Cardiovascular Agents administration & dosage, Coated Materials, Biocompatible, Coronary Angiography, Coronary Stenosis therapy, Coronary Vessels diagnostic imaging, Multimodal Imaging methods, Percutaneous Coronary Intervention instrumentation, Sirolimus administration & dosage, Tomography, Optical Coherence
- Abstract
Objectives: The primary objective of this study was to evaluate the safety and effectiveness of the Mirage (Manli Cardiology, Singapore) bioresorbable microfiber sirolimus-eluting scaffold compared with the Absorb (Abbott Vascular, Santa Clara, California) bioresorbable vascular scaffold in the treatment of stenotic target lesions located in native coronary arteries, ranging from ≥2.25 to ≤4.0 mm in diameter. Secondary objectives were to establish the medium-term safety, effectiveness, and performance of the Mirage device., Background: The current generation of bioresorbable scaffolds has several limitations, such as thick square struts with large footprints that preclude their deep embedment into the vessel wall, resulting in protrusion into the lumen with microdisturbance of flow. The Mirage sirolimus-eluting bioresorbable microfiber scaffold is designed to address these concerns., Methods: In this prospective, single-blind trial, 60 patients were randomly allocated in a 1:1 ratio to treatment with a Mirage sirolimus-eluting bioresorbable microfiber scaffold or an Absorb bioresorbable vascular scaffold. The clinical endpoints were assessed at 30 days and at 6 and 12 months. In-device angiographic late loss at 12 months was quantified. Secondary optical coherence tomographic endpoints were assessed post-scaffold implantation at 6 and 12 months., Results: Median angiographic post-procedural in-scaffold minimal luminal diameters of the Mirage and Absorb devices were 2.38 mm (interquartile range [IQR]: 2.06 to 2.62 mm) and 2.55 mm (IQR: 2.26 to 2.71 mm), respectively; the effect size (d) was -0.29. At 12 months, median angiographic in-scaffold minimal luminal diameters of the Mirage and Absorb devices were not statistically different (1.90 mm [IQR: 1.57 to 2.31 mm] vs. 2.29 mm [IQR: 1.74 to 2.51 mm], d = -0.36). At 12-month follow-up, median in-scaffold late luminal loss with the Mirage and Absorb devices was 0.37 mm (IQR: 0.08 to 0.72 mm) and 0.23 mm (IQR: 0.15 to 0.37 mm), respectively (d = 0.20). On optical coherence tomography, post-procedural diameter stenosis with the Mirage was 11.2 ± 7.1%, which increased to 27.4 ± 12.4% at 6 months and remained stable (31.8 ± 12.9%) at 1 year, whereas the post-procedural optical coherence tomographic diameter stenosis with the Absorb was 8.4 ± 6.6%, which increased to 16.6 ± 8.9% and remained stable (21.2 ± 9.9%) at 1-year follow-up (Mirage vs. Absorb: d
post-procedure = 0.41, d6 months = 1.00, d12 months = 0.92). Angiographic median in-scaffold diameter stenosis was significantly different between study groups at 12 months (28.6% [IQR: 21.0% to 40.7%] for the Mirage, 18.2% [IQR: 13.1% to 31.6%] for the Absorb, d = 0.39). Device- and patient-oriented composite endpoints were comparable between the 2 study groups., Conclusions: At 12 months, angiographic in-scaffold late loss was not statistically different between the Mirage and Absorb devices, although diameter stenosis on angiography and on optical coherence tomography was significantly higher with the Mirage than with the Absorb. The technique of implantation was suboptimal for both devices, and future trials should incorporate optical coherence tomographic guidance to allow optimal implantation and appropriate assessment of the new technology, considering the novel mechanical properties of the Mirage., (Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
28. Impact of the Occlusion Duration on the Performance of J-CTO Score in Predicting Failure of Percutaneous Coronary Intervention for Chronic Total Occlusion.
- Author
-
de Castro-Filho A, Lamas ES, Meneguz-Moreno RA, Staico R, Siqueira D, Costa RA, Braga SN, Costa JR Jr, Chamié D, and Abizaid A
- Subjects
- Aged, Chronic Disease, Coronary Angiography, Coronary Occlusion diagnosis, Female, Follow-Up Studies, Humans, Japan epidemiology, Male, Middle Aged, Postoperative Complications epidemiology, Predictive Value of Tests, ROC Curve, Retrospective Studies, Risk Factors, Severity of Illness Index, Time Factors, Treatment Failure, Coronary Occlusion surgery, Percutaneous Coronary Intervention adverse effects, Postoperative Complications diagnosis, Registries, Risk Assessment
- Abstract
Objectives: The present study examined the association between Multicenter CTO Registry in Japan (J-CTO) score in predicting failure of percutaneous coronary intervention (PCI) correlating with the estimated duration of chronic total occlusion (CTO)., Background: The J-CTO score does not incorporate estimated duration of the occlusion., Methods: This was an observational retrospective study that involved all consecutive procedures performed at a single tertiary-care cardiology center between January 2009 and December 2014., Results: A total of 174 patients, median age 59.5 years (interquartile range [IQR], 53-65 years), undergoing CTO-PCI were included. The median estimated occlusion duration was 7.5 months (IQR, 4.0-12.0 months). The lesions were classified as easy (score = 0), intermediate (score = 1), difficult (score = 2), and very difficult (score ≥3) in 51.1%, 33.9%, 9.2%, and 5.7% of the patients, respectively. Failure rate significantly increased with higher J-CTO score (7.9%, 20.3%, 50.0%, and 70.0% in groups with J-CTO scores of 0, 1, 2, and ≥3, respectively; P<.001). There was no significant difference in success rate according to estimated duration of occlusion (P=.63). Indeed, J-CTO score predicted failure of CTO-PCI independently of the estimated occlusion duration (P=.24). Areas under receiver-operating characteristic curves were computed and it was observed that for each occlusion time period, the discriminatory capacity of the J-CTO score in predicting CTO-PCI failure was good, with a C-statistic >0.70., Conclusion: The estimated duration of occlusion had no influence on the J-CTO score performance in predicting failure of PCI in CTO lesions. The probability of failure was mainly determined by grade of lesion complexity.
- Published
- 2017
29. Pressure-mediated versus pharmacologic treatment of radial artery spasm during cardiac catheterisation: a randomised pilot study.
- Author
-
Collet C, Corral JM, Cavalcante R, Tateishi H, Belzarez O, Ribamar Costa J, Costa R, Chamié D, Onuma Y, de Winter RJ, Abizaid A, and Serruys PW
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Nitroglycerin administration & dosage, Pilot Projects, Prospective Studies, Vascular Patency drug effects, Vasodilation, Verapamil administration & dosage, Cardiac Catheterization adverse effects, Radial Artery diagnostic imaging, Spasm therapy
- Abstract
Aims: The aim of the study was to determine the effectiveness of a novel strategy to treat radial artery spasm (RAS)., Methods and Results: We conducted a prospective, randomised, single-centre, open-label trial comparing a novel strategy of pressure-mediated dilatation versus intra-arterial administration of a combination of nitroglycerine plus verapamil for the treatment of RAS. The primary endpoint was radial artery intraluminal diameter acute gain assessed by quantitative radial angiography. After screening two hundred and twenty consecutive cases, twenty patients presented with RAS and were randomised 1:1 to either strategy. Overall the mean age was 60.8±11.5 years and 53% were females. Pre-treatment angiographic characteristics were similar between the groups. The primary endpoint of radial artery acute gain was significantly greater in the pressure-mediated dilatation group (0.85±0.46 mm vs. 0.03±0.24 mm, p<0.001). Blood pressure drop was significantly lower in the pressure-mediated dilatation group (ΔBP -3.8±24 vs. -31.6±19 mmHg, p<0.001). There was one case of radial artery occlusion in the pressure-mediated dilatation group at follow-up. Short-duration pain was observed during the application of pressure., Conclusions: Pressure-mediated dilatation for the treatment of RAS was feasible, with superior angiographic results compared to a pharmacologic vasodilator strategy, with no impact on blood pressure. This novel approach proved to be safe and effective and should be tested in a large randomised trial.
- Published
- 2017
- Full Text
- View/download PDF
30. Intravascular imaging comparison of two metallic limus-eluting stents abluminally coated with biodegradable polymers: IVUS and OCT results of the DESTINY trial.
- Author
-
Costa JR Jr, Chamié D, Abizaid AA, Ribeiro E, Meireles GC, Prudente M, Campos CA, Castro JP, Costa R, and Lemos PA
- Subjects
- Cardiovascular Agents adverse effects, Humans, Neointima, Percutaneous Coronary Intervention adverse effects, Predictive Value of Tests, Prosthesis Design, Sirolimus administration & dosage, Sirolimus adverse effects, Time Factors, Treatment Outcome, Absorbable Implants, Cardiovascular Agents administration & dosage, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Vessels diagnostic imaging, Coronary Vessels drug effects, Drug-Eluting Stents, Metals, Percutaneous Coronary Intervention instrumentation, Polymers chemistry, Sirolimus analogs & derivatives, Tomography, Optical Coherence, Ultrasonography, Interventional
- Abstract
We sought to compare, by means of IVUS and OCT imaging, the performance of a novel sirolimus-eluting drug-eluting stent (DES) with biodegradable polymer (Inspiron™) to the Biomatrix™ DES. From the DESTINY trial, a total of 70 randomized patients (2:1) were enrolled in the IVUS substudy (Inspiron™, n = 46; Biomatrix™: n = 20) while 25 patients were evaluated with OCT (Inspiron™, n = 19; Biomatrix™: n = 06) at 9-month follow-up. The main endpoints were % of neointimal tissue obstruction (IVUS) and neointimal stut coverage (OCT) at 9 months. Patients treated with both DES had very little NIH formation at 9 months either by IVUS (% of NIH obstruction of 4.9 ± 4.1 % with Inspiron™ vs. 2.7 ± 2.9 % with Biomatrix™, p = 0.03) or by OCT (neointimal thickness of 144.2 ± 72.5 µm Inspiron™ vs. 115.0 ± 53.9 µm with Biomatrix™, p = 0.45). Regarding OCT strut-level assessment, again both devices showed excellent 9-month performance, with high rates of strut coverage (99.49 ± 1.01 % with Inspiron™ vs. 97.62 ± 2.21 % with Biomatrix™, p < 0.001) and very rare malapposition (0.29 ± 1.06 % with Inspiron™ vs. 0.53 ± 0.82 % with Biomatrix™, p = 0.44). Patients with any uncovered struts were more frequently identified in the Biomatrix™ group (9.78 ± 7.13 vs. 2.29 ± 3.91 %, p < 0.001). In the present study, midterm IVUS and OCT evaluations showed that both new generation DES with biodegradable polymer were effective in terms of suppressing excessive neointimal response, with very high rates of apposed and covered struts, suggesting a consistent and benign healing pattern.
- Published
- 2017
- Full Text
- View/download PDF
31. First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study.
- Author
-
Worthley SG, Abizaid A, Kirtane AJ, Simon DI, Windecker S, Brar S, Meredith IT, Shetty S, Sinhal A, Almonacid AP, Chamié D, Maehara A, and Stone GW
- Subjects
- Australia, Chromium Alloys, Coronary Artery Disease diagnostic imaging, Coronary Restenosis etiology, Coronary Thrombosis diagnostic imaging, Coronary Thrombosis etiology, Drug Therapy, Combination, Female, Humans, Latin America, Male, Middle Aged, Myocardial Infarction diagnostic imaging, Myocardial Infarction etiology, Percutaneous Coronary Intervention adverse effects, Platelet Aggregation Inhibitors administration & dosage, Predictive Value of Tests, Prosthesis Design, Risk Factors, Singapore, Sirolimus administration & dosage, Sirolimus analogs & derivatives, Tantalum, Time Factors, Treatment Outcome, Coronary Angiography, Coronary Artery Disease therapy, Coronary Restenosis diagnostic imaging, Coronary Vessels diagnostic imaging, Drug-Eluting Stents, Percutaneous Coronary Intervention instrumentation, Tomography, Optical Coherence, Ultrasonography, Interventional
- Abstract
Objectives: This study sought to assess the safety and effectiveness of the drug-filled stent (DFS) (Medtronic, Santa Rosa, California) in the treatment of patients with coronary artery disease., Background: Polymer-free drug-eluting stents have the potential to improve clinical outcomes and facilitate shorter durations of dual antiplatelet therapy. The polymer-free DFS is made from a trilayered continuous wire with an outer cobalt chromium layer, a middle tantalum layer, and an inner lumen coated with sirolimus. Small laser-drilled holes on the abluminal stent surface control drug elution., Methods: The RevElution trial enrolled 100 patients with de novo coronary lesions 2.25 to 3.50 mm in diameter and length ≤27 mm in 2 cohorts of 50 patients for angiographic, intravascular ultrasound, and clinical assessment at 9 or 24 months, with optical coherence tomography performed in a subset of 30 patients at each time period. The primary endpoint was angiographic in-stent late lumen loss at 9 months compared with Resolute zotarolimus-eluting stent (Medtronic) historical control data., Results: Fifty patients with 56 lesions were treated with DFS in the 9-month cohort. In-stent late lumen loss was 0.26 ± 0.28 mm for DFS and 0.36 ± 0.52 mm for Resolute (p
noninferiority <0.001). The binary angiographic restenosis rate was 0%. Median stent strut coverage by optical coherence tomography was 91.4%, 95.6%, and 99.1% at 1, 3, and 9 months, respectively. One non-Q-wave myocardial infarction occurred, with a 9-month target lesion failure rate of 2.1%. No stent thrombosis occurred., Conclusions: At 9 months, the polymer-free DFS was safe and effective with high rates of early strut coverage and noninferior late lumen loss compared to Resolute. (Medtronic RevElution Trial [RevElution]; NCT02480348)., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
32. Role of invasive imaging in acute and long-term assessment of bioresorbable scaffold technology.
- Author
-
Chamié D, Garcia-Garcia H, Costa RA, Onuma Y, Abizaid A, and Serruys PW
- Subjects
- Coronary Artery Disease surgery, Follow-Up Studies, Humans, Time Factors, Tomography, Optical Coherence, Absorbable Implants, Coronary Artery Disease diagnosis, Diagnostic Imaging methods, Drug-Eluting Stents, Percutaneous Coronary Intervention methods, Tissue Scaffolds
- Abstract
Fully bioresorbable scaffolds (BRS) represent a novel approach for the percutaneous treatment of coronary artery stenosis, providing temporary vessel scaffolding with drug-eluting capability during the restenosis-prone phase of the vascular healing. Beyond this initial critical period, when mechanical scaffolding support is no longer necessary, the device is bioresorbed, restoring the normal vascular physiology with the aim to eliminate the long-term safety concerns related to permanent metallic implants. Nonetheless, current BRS technology suffers from limited mechanical properties as compared to available metallic platforms, requiring careful attention to lesion preparation, accurate vessel sizing, and implantation technique. Intravascular imaging has played an important role in providing knowledge on the acute effects after BRS deployment, and it helped refine the current technique of BRS implantation. In addition, extensive work with multiple intravascular imaging modalities have also contributed to the understanding of the unique dynamic vascular changes that are experienced in the treated segment from post-implantation up to complete device bioresorption. In this manuscript, we review the role of invasive imaging modalities-from angiography to sound- and light-based techniques-to guide BRS implantation procedures, to assess its acute results postimplantation, and the changes experienced in the long-term until complete bioresorption has ensued. © 2016 Wiley Periodicals, Inc., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
33. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
- Author
-
Abizaid A, Costa RA, Schofer J, Ormiston J, Maeng M, Witzenbichler B, Botelho RV, Costa JR Jr, Chamié D, Abizaid AS, Castro JP, Morrison L, Toyloy S, Bhat V, Yan J, and Verheye S
- Subjects
- Aged, Brazil, Cardiovascular Agents adverse effects, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Coronary Vessels diagnostic imaging, Europe, Female, Humans, Hyperplasia, Macrolides adverse effects, Male, Middle Aged, Neointima, New Zealand, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, Predictive Value of Tests, Prospective Studies, Time Factors, Treatment Outcome, Absorbable Implants, Cardiovascular Agents administration & dosage, Coated Materials, Biocompatible, Coronary Angiography, Coronary Artery Disease therapy, Coronary Vessels drug effects, Macrolides administration & dosage, Percutaneous Coronary Intervention instrumentation, Tomography, Optical Coherence, Ultrasonography, Interventional
- Abstract
Objectives: This study sought to report the late multimodality imaging and clinical outcomes of the novel poly-l-lactic-acid-based DESolve novolimus-eluting bioresorbable coronary scaffold for the treatment of de novo coronary lesions., Background: Bioresorbable scaffolds are an alternative to drug-eluting metallic stents and provide temporary vascular scaffolding, which potentially may allow vessel restoration and reduce the risk of future adverse events., Methods: Overall, 126 patients were enrolled at 13 international sites between November 2011 and June 2012. The primary endpoint was in-scaffold late lumen loss at 6 months. Major adverse cardiac events, the main safety endpoint, were defined as the composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization. All patients underwent angiography at 6 months. Serial intravascular ultrasound and optical coherence tomography were performed in a subset of patients., Results: The scaffold device success rate was 97% (n = 122 of 126), and procedural success was 100% (n = 122 of 122). The major adverse cardiac event rate was 3.3% (n = 4 of 122) at 6 months and 7.4% (n = 9 of 122) at 24 months, including 1 probable stent thrombosis within the first month. At 6-month angiographic follow-up, in-scaffold late lumen loss was 0.20 ± 0.32 mm. Paired intravascular ultrasound analysis demonstrated a significant increase in vessel, lumen and scaffold dimensions between post-procedure and 6-month follow-up, and strut-level optical coherence tomography analysis showed full strut coverage in 99 ± 1.7%., Conclusions: Our results showed favorable performance of the DESolve scaffold, effective inhibition of neointimal hyperplasia, and for the first time, early luminal and scaffold growth at 6 months with sustained efficacy and safety through 2 years. (Elixir Medical Clinical Evaluation of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System-The DESolve Nx Trial; NCT02086045)., (Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
34. Clinical, angiographic, and intravascular ultrasound results of the VestSaync II trial.
- Author
-
Costa JR Jr, Oliveira BA, Abizaid A, Costa R, Perin M, Abizaid A, Chamié D, Fernando Tanajura L, Sousa A, and Sousa JE
- Subjects
- Coronary Artery Disease diagnostic imaging, Double-Blind Method, Drug-Eluting Stents, Electrocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Prosthesis Design, Treatment Outcome, Coated Materials, Biocompatible, Coronary Angiography methods, Coronary Artery Disease surgery, Percutaneous Coronary Intervention methods, Stents, Ultrasonography, Interventional methods
- Abstract
Aim: We sought to assess the long term efficacy of the novel VESTAsync™ Eluting Stent (VES) combining a Cro-Co platform with a nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-free low-dose of Sirolimus (55 μg)., Methods: The Vestasync II trial was a randomized (2:1), double-blinded, multicenter comparison of the VES to its platform, the Gen X stent, with microporous hydroxyapatite surface coating without sirolimus. Patients were eligible if they presented de novo lesions in native coronary arteries with 3.0-3.5 mm diameter and ≤ 14 mm in length. Primary endpoint was 8-month in-stent late loss and % of stent obstruction. Lifelong aspirin and 6-month clopidogrel were prescribed to all patients., Results: Seventy-five patients were enrolled (VES = 50 pts). Baseline characteristics included mean age of 58 years and 29% of diabetics. Reference vessel diameter and lesion length were 2.8 ± 0.4 mm and 13.0 ± 2.0 mm, respectively. In-stent late loss (0.39 ± 0.20 vs. 0.74 ± 0.52, P = 0.03) and % of neointima hyperplasia (9.3 ± 6.6% vs. 17.6 ± 9.4%, P = 0.0016) were significantly reduced in the VES cohort. Up to 1 year, there was a single case of myocardial infarction and one target lesion revascularization (TLR) (2%) in the VES group while in the control cohort there were one TLR (4%) and one cardiac death (4%)., Conclusion: The VestSync II trial is a proof-of-concept study and demonstrates the sustained efficacy of this novel polymer-free sirolimus drug-eluting stents. A larger trial, with more complex lesions, clinical endpoints and longer FU period is warranted. © 2013 Wiley Periodicals, Inc., (© 2013 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
35. Factors associated with progression of coronary artery disease measured by intravascular ultrasound: systematic review and meta-analysis.
- Author
-
Nascimento BR, de Sousa MR, Demarqui FN, Chamié D, Marcolino MS, Biondi-Zoccai G, Boersma E, Ribeiro AL, and Costa MA
- Subjects
- Coronary Artery Disease drug therapy, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Randomized Controlled Trials as Topic methods, Coronary Artery Disease diagnostic imaging, Disease Progression, Ultrasonography, Interventional methods
- Published
- 2014
- Full Text
- View/download PDF
36. A journey into the carotid artery microenvironment in high resolution: challenging the stenosis-symptoms paradigm.
- Author
-
Abizaid A and Chamié D
- Subjects
- Female, Humans, Male, Carotid Arteries pathology, Carotid Artery Diseases diagnosis, Tomography, Optical Coherence methods
- Published
- 2014
- Full Text
- View/download PDF
37. Frequency-domain optical coherence tomography assessment of unprotected left main coronary artery disease-a comparison with intravascular ultrasound.
- Author
-
Fujino Y, Bezerra HG, Attizzani GF, Wang W, Yamamoto H, Chamié D, Kanaya T, Mehanna E, Tahara S, Nakamura S, and Costa MA
- Subjects
- Aged, Contrast Media, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease pathology, Coronary Artery Disease therapy, Feasibility Studies, Female, Humans, Male, Middle Aged, Percutaneous Coronary Intervention instrumentation, Pilot Projects, Predictive Value of Tests, Prospective Studies, Risk Factors, Severity of Illness Index, Stents, Time Factors, Treatment Outcome, Wound Healing, Coronary Artery Disease diagnosis, Coronary Vessels diagnostic imaging, Coronary Vessels pathology, Tomography, Optical Coherence adverse effects, Ultrasonography, Interventional adverse effects
- Abstract
Objectives: To investigate safety and feasibility of imaging unprotected left main (ULM) using frequency-domain optical coherence tomography (FD-OCT) compared with intravascular ultrasound (IVUS)., Background: IVUS has been used to assess and guide percutaneous coronary intervention (PCI) of ULM disease. FD-OCT offers 10-fold higher axial resolution than IVUS and its high-speed image acquisition obviates the need for proximal balloon occlusion., Methods: We prospectively enrolled 35 consecutive patients with ULM disease. FD-OCT and IVUS assessments were attempted pre- and post-PCI and compared in regards to safety, ability to image the region of interest (ROI), number of pullbacks, volume of contrast and ability to detect malapposition, dissection, and thrombus., Results: Patients were followed for 1 year when FD-OCT imaging was repeated. FD-OCT required more repeated pullbacks to image the ROI compared to IVUS. Mean lumen and stent areas were similar between FD-OCT and IVUS (11.24 ± 2.66 vs. 10.85 ± 2.47 mm(2) , P = 0.13 and 10.44 ± 2.33 vs. 10.49 ± 2.32 mm(2) , P = 0.82, respectively), whereas imaged stent length was shorter with FD-OCT. Malapposition areas and volumes were larger and more edge dissections were detected by FD-OCT. There were no clinical adverse events and no complications associated with FD-OCT at baseline and 1-year follow-up. All dissections were healed, whereas stent malapposition was still detected at follow-up., Conclusions: FD-OCT assessment of ULM is feasible and safe. Direct comparisons with IVUS reveal that FD-OCT achieved imaging completeness less often, whereas it was more sensitive in detecting malapposition and edge dissections, and similar to IVUS in the assessment of lumen and stent dimensions., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
38. Incidence, predictors, morphological characteristics, and clinical outcomes of stent edge dissections detected by optical coherence tomography.
- Author
-
Chamié D, Bezerra HG, Attizzani GF, Yamamoto H, Kanaya T, Stefano GT, Fujino Y, Mehanna E, Wang W, Abdul-Aziz A, Dias M, Simon DI, and Costa MA
- Subjects
- Aged, Coronary Angiography, Coronary Artery Disease diagnosis, Female, Heart Injuries epidemiology, Heart Injuries therapy, Humans, Incidence, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Predictive Value of Tests, Risk Factors, Stents, Time Factors, Treatment Outcome, Vascular System Injuries epidemiology, Vascular System Injuries therapy, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary instrumentation, Coronary Artery Disease therapy, Coronary Vessels injuries, Coronary Vessels pathology, Heart Injuries pathology, Tomography, Optical Coherence, Vascular System Injuries pathology
- Abstract
Objectives: This study sought to investigate the frequency, predictors, and detailed qualitative and quantitative assessment of optical coherence tomography (OCT)-detected stent edge dissections. Its impact on subsequent management and clinical outcomes were also investigated., Background: OCT is a high-resolution imaging modality that can lead to more frequent recognition and accurate assessment of vascular injuries during percutaneous coronary intervention (PCI)., Methods: From September 2010 to June 2011, all patients with OCT post-PCI were enrolled. Edge dissections were defined as disruptions of the arterial lumen surface in both the 5-mm distal and proximal stent edges. Qualitative and quantitative analyses of all edges were performed at 0.2-mm intervals., Results: In total, 395 edges (249 lesions in 230 patients) were analyzed. The overall incidence of OCT-detected edge dissection was 37.8%, and most (84%) were not apparent on angiography. Independent predictors for OCT-detected dissections were presence of atherosclerotic plaque at stent edges, calcification angle, minimum fibrous cap thickness, thin-cap fibroatheromas, stent/lumen eccentricity, and vessel overstretching. Mean dissection length measured 2.04 ± 1.60 mm, 96.2% appeared as flaps, and 52.8% extended beyond the intima/atheroma layer. Additional stenting was performed in 22.6% of all dissections, which were longer, had bigger dimensions, and promoted deeper vascular injury. The 12-month major adverse cardiac event rate was similar between patients with (7.95%) and without (5.69%, p = 0.581) dissections., Conclusions: High rates of stent edge dissections were detected by OCT, usually related to the presence of atherosclerosis at stent edges and to PCI technique. Detailed OCT assessment of dissection severity was possible and affected the subsequent management of this complication. Non-flow-limiting, small, and superficial dissections left untreated proved benign., (Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
39. Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography.
- Author
-
Staico R, Costa MA, Chamié D, Bezerra H, Armaganijan LV, Costa RA, Costa JR, Siqueira D, Centemero M, Chaves Á, Tanajura LF, Abizaid A, Feres F, Sousa JE, and Sousa AG
- Subjects
- Aged, Coronary Angiography, Coronary Artery Disease diagnosis, Coronary Restenosis etiology, Coronary Restenosis pathology, Coronary Vessels diagnostic imaging, Female, Humans, Male, Middle Aged, Neointima, Percutaneous Coronary Intervention adverse effects, Predictive Value of Tests, Prosthesis Design, Sirolimus administration & dosage, Time Factors, Treatment Outcome, Ultrasonography, Interventional, Cardiovascular Agents administration & dosage, Coronary Artery Disease therapy, Coronary Restenosis diagnosis, Coronary Vessels pathology, Drug-Eluting Stents, Percutaneous Coronary Intervention instrumentation, Sirolimus analogs & derivatives, Tomography, Optical Coherence
- Abstract
First generation drug-eluting stents (DES) are associated with reduced in-stent restenosis but significant increased risk of very late stent thrombosis (VLST). The absence of polymer in DES systems may reduce the occurrence of VLST. Optic coherence tomography (OCT) has been used for stent analysis as a surrogate safety endpoint. This study aimed to assess the long-term follow up of strut apposition and tissue coverage of BioMatrix DES by OCT. 20 patients undergoing BioMatrix DES (n = 15) or S-Stent BMS (n = 5) implantation were followed for at least 5 years and evaluated by quantitative coronary angiography, intravascular ultrasound, and OCT. The difference between the stent types was evaluated by nonparametric Mann-Whitney U test while categorical variables were evaluated by Fisher exact test. Rates of in-stent late loss were similar between groups [0.40 (0.21;0.77) vs. 0.68 (0.66; 0.82) mm, p = 0.205, for BioMatrix and S-Stent, respectively]. The vessel, stent and lumen volumes did not differ between groups. Patients treated with BioMatrix had significantly less stent obstruction [5.6 (4.4;9.7) vs. 28.6 (24.7;29.0) %, p = 0.001]. OCT analysis of 12 stents (Biomatrix = 9 and S-Stent = 3) demonstrated 126 (8.7 %) uncovered struts in the BioMatrix group compared to 23 (4.0 %) in the S-Stent group (p = 0.297), being the majority of them well apposed (117/126 and 21/23, respectively, p = 0.292). Only 9 (0.6 %) struts in the DES and 2 (0.4 %) struts in the BMS groups were simultaneously uncovered and malapposed (p = 0.924). BioMatrix DES was associated with lower rates of in-stent obstruction, and similar percentage of neointimal coverage on struts and of complete strut apposition.
- Published
- 2013
- Full Text
- View/download PDF
40. Unrestricted utilization of frequency domain optical coherence tomography in coronary interventions.
- Author
-
Stefano GT, Bezerra HG, Mehanna E, Yamamoto H, Fujino Y, Wang W, Attizzani G, Chamié D, Simon DI, and Costa MA
- Subjects
- Aged, Coronary Angiography, Coronary Vessels diagnostic imaging, Female, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Ohio, Predictive Value of Tests, Prospective Studies, Stents, Treatment Outcome, Coronary Artery Disease diagnosis, Coronary Artery Disease therapy, Coronary Vessels pathology, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention instrumentation, Tomography, Optical Coherence
- Abstract
Frequency domain optical coherence tomography (FD-OCT) has shown promise to evaluate coronary devices in clinical trials, however, little is known about its application in clinical practice. This prospective, single center initiative planned for 100 % FD-OCT utilization in all patients undergoing coronary interventions during a 60-day period. Operators pre-specified the planned intervention based on angiography alone. FD-OCT success was defined as acquisition of good quality images enabling adequate quantification of vessel dimensions and lesion/percutaneous coronary intervention (PCI) assessment. Impact on management occurred when angiography-based planning was altered based on FD-OCT data. There were 297 FD-OCT acquisitions performed in 155 vessels from 150 patients. There were no FD-OCT procedural related cardiac adverse events and success was obtained in 85.7 % of all target vessels (pre-PCI = 76.8 % vs. post-PCI = 90.1 %, p = 0.004). Success on the first pullback occurred in 80.3 % overall (61.9 % in the initial operator experience and 85.5 % after the third procedure). FD-OCT impact on management was 81.8 % pre-PCI and 54.8 % post-PCI. Stent malapposition was detected in 39.2 % (89.4 % underwent further intervention) and edge dissection in 32.5 % (21.1 % treated with stent). FD-OCT success and management impact were similar in ACS and non-ACS patients (82.1 vs. 81.1 %, p = 1.000, and 62.5 vs. 65.1 %, p = 0.854, respectively). FD-OCT is safe, can successfully be incorporated into routine practice, and alters procedural strategy in a high proportion of patients undergoing PCI.
- Published
- 2013
- Full Text
- View/download PDF
41. Volumetric characterization of human coronary calcification by frequency-domain optical coherence tomography.
- Author
-
Mehanna E, Bezerra HG, Prabhu D, Brandt E, Chamié D, Yamamoto H, Attizzani GF, Tahara S, Van Ditzhuijzen N, Fujino Y, Kanaya T, Stefano G, Wang W, Gargesha M, Wilson D, and Costa MA
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Calcium, Coronary Artery Disease metabolism, Coronary Artery Disease pathology, Coronary Vessels metabolism, Coronary Vessels pathology, Plaque, Atherosclerotic metabolism, Plaque, Atherosclerotic pathology, Tomography, Optical Coherence, Vascular Calcification metabolism, Vascular Calcification pathology
- Abstract
Background: Coronary artery calcification (CAC) presents unique challenges for percutaneous coronary intervention. Calcium appears as a signal-poor region with well-defined borders by frequency-domain optical coherence tomography (FD-OCT). The objective of this study was to demonstrate the accuracy of intravascular FD-OCT to determine the distribution of CAC., Methods and Results: Cadaveric coronary arteries were imaged using FD-OCT at 100-μm frame interval. Arteries were subsequently frozen, sectioned and imaged at 20-μm intervals using the Case Cryo-Imaging automated system(TM). Full volumetric co-registration between FD-OCT and cryo-imaging was performed. Calcium area, calcium-lumen distance (depth) and calcium angle were traced on every cross-section; volumetric quantification was performed offline. In total, 30 left anterior descending arteries were imaged: 13 vessels had a total of 55 plaques with calcification by cryo-imaging; FD-OCT identified 47 (85%) of these plaques. A total of 1,285 cryo-images were analyzed and compared with corresponding co-registered 257 FD-OCT images. Calcium distribution, represented by the mean depth and the mean calcium angle, was similar, with excellent correlation between FD-OCT and cryo-imaging respectively (mean depth: 0.25±0.09 vs. 0.26±0.12mm, P=0.742; R=0.90), (mean angle: 35.33±21.86° vs. 39.68±26.61°, P=0.207; R=0.90). Calcium volume was underestimated in large calcifications (3.11±2.14 vs. 4.58±3.39mm(3), P=0.001) in OCT vs. cryo respectively., Conclusions: Intravascular FD-OCT can accurately characterize CAC distribution. OCT can quantify absolute calcium volume, but may underestimate calcium burden in large plaques with poorly defined abluminal borders.
- Published
- 2013
- Full Text
- View/download PDF
42. Serial Evaluation of Vascular Response After Implantation of a New Sirolimus-Eluting Stent With Bioabsorbable Polymer (MISTENT): an optical coherence tomography and histopathological study.
- Author
-
Attizzani GF, Bezerra HG, Chamié D, Fujino Y, Spognardi AM, Stanley JR, Yamamoto H, Mehanna E, Wang W, Carlyle WC, McClain JB, and Costa MA
- Subjects
- Animals, Coronary Angiography, Coronary Restenosis pathology, Coronary Restenosis prevention & control, Coronary Vessels diagnostic imaging, Disease Models, Animal, Endothelium, Vascular pathology, Follow-Up Studies, Neointima pathology, Percutaneous Coronary Intervention methods, Swine, Swine, Miniature, Time Factors, Absorbable Implants, Coronary Vessels pathology, Drug-Eluting Stents, Percutaneous Coronary Intervention instrumentation, Sirolimus, Tomography, Optical Coherence
- Abstract
Background: Novel vascular scaffolds aim at equipoise between safety and efficacy. Intravascular optical coherence tomography (OCT) allows in-vivo serial assessment of stent-vessel interactions with high resolution and frequent sampling and may complement histology assessment. We investigated the vascular response to a novel absorbable coating sirolimus-eluting stent (AC-SES) by means of serial OCT and histology evaluation in a porcine model., Methods: One AC-SES and one bare-metal stent (BMS) were implanted in separate coronary arteries of three Yucatan mini-swine. Serial OCT was performed post procedure and at 3-, 28-, 90-, and 180-day follow-up. Normalized optical density (NOD) was used for the assessment of tissue response over time. Histological evaluation was performed at day 180., Results: A total of 6408 stent struts were analyzed. OCT revealed 100% of struts covered at 28 days, and a significant difference in NOD from 3 to 28 days (0.64 ± 0.07 vs 0.71 ± 0.05, respectively; P<.001) in the AC-SES group. Neointimal thickness was 0.14 ± 0.08 mm, 0.17 ± 0.11 mm, and 0.16 ± 0.09 mm in the AC-SES group and 0.18 ± 0.10 mm, 0.14 ± 0.09 mm, and 0.10 ± 0.08 mm in the BMS group, while rates of uncovered struts were 0%, 0%, and 3.1% and 1.4%, 7.8%, and 21.5%, respectively, at 28, 90, and 180 days. Minimal inflammation and a mature endothelialization were demonstrated in both groups by histology., Conclusion: OCT serial assessment of vascular response suggested NIH maturation 28 days following AC-SES implantation in pigs. These findings, coupled with histological demonstration of low inflammation scores and complete endothelial coverage as measured at 180 days, suggest a satisfactory healing response to AC-SES.
- Published
- 2012
43. Serial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents.
- Author
-
Ribamar Costa J Jr, Abizaid A, Sousa A, Siqueira D, Chamié D, Feres F, Costa R, Staico R, Maldonado G, Centemero M, Tanajura LF, Viana R, Chaves Á, Abizaid A, and Sousa JE
- Subjects
- Acute Coronary Syndrome diagnostic imaging, Aged, Coronary Angiography, Female, Humans, Male, Metals, Middle Aged, Prospective Studies, Acute Coronary Syndrome therapy, Angioplasty, Balloon, Coronary, Coronary Vessels pathology, Drug-Eluting Stents, Plaque, Atherosclerotic prevention & control, Stents, Ultrasonography, Interventional
- Abstract
Background: Little is known about the correlation between modifications in plaque composition at stent edges and the changes in vessel geometry. This study sought to evaluate, by serial greyscale intravascular ultrasound (IVUS) and Virtual Histology intravascular ultrasound (VH-IVUS), the modifications in plaque composition at the edges of drug-eluting and bare metal stents and the correlation of these findings with changes in the measurements of vessel, lumen and plaque area at those segments., Methods and Results: Single-centre, prospective and randomised (1:1) evaluation of 40 patients with acute coronary syndrome treated with bare metal (Driver; Medtronic, Santa Clara, CA, USA; n=20 patients) or drug-eluting stents (Cypher; Cordis, Miami Lakes, FL, USA; n=20 patients). IVUS and VH-IVUS assessments were done post-procedure and at nine months. Primary endpoint included the modification in vessel, lumen and plaque area and in the composition of the plaque in the mean time between the baseline and follow-up procedure. At the proximal edge of the vessel treated with the Cypher stent, a trend toward positive vessel remodelling (D=+0.6 mm², p=0.06) was observed while at the distal edge, less plaque growth (D=+0.2 mm² vs. D=+1.1 mm², p<0.001), resulted in a larger lumen area at follow-up. By VH, there was a marked reduction in the percentage of fibrotic tissue and necrotic core at the edges of both stents and a positive correlation was seen between increase in percentage of fibro-fatty component and increase in plaque area (r=0.78, p=0.01)., Conclusion: Patients treated with drug-eluting stents (DES) experienced less plaque growth, especially at the distal edge of the stents. Modifications in plaque composition, with increase in fibrofatty tissue component, may partially explain these findings.
- Published
- 2012
- Full Text
- View/download PDF
44. Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents.
- Author
-
Collet CA, Costa JR, Abizaid A, Chamié D, Staico R, Costa R, Siquera D, Obregon J, Feres F, Sousa A, and Sousa JE
- Subjects
- Clopidogrel, Coronary Angiography, Coronary Restenosis etiology, Diabetes Mellitus pathology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neointima diagnostic imaging, Risk Factors, Statistics as Topic, Statistics, Nonparametric, Ticlopidine analogs & derivatives, Ticlopidine therapeutic use, Time Factors, Ultrasonography, Interventional, Coronary Restenosis pathology, Drug-Eluting Stents adverse effects, Immunosuppressive Agents therapeutic use, Neointima etiology, Sirolimus therapeutic use
- Abstract
Objectives: This study sought to assess the temporal course of neointimal hyperplasia (NIH) formation following implantation of 2 different generations of drug-eluting stents (DES)., Background: The amount of NIH following DES implantation correlates with the potency of the antiproliferative drug, its kinetic release, as well as some individual characteristics, as the presence of diabetes mellitus (DM). Recently, some publications have suggested a continuous growth of NIH following DES, which in some cases, might result in late "catch-up.", Methods: Twenty-five patients with single, de novo lesions were treated with sirolimus-eluting stents (SES) (n = 12) and biolimus-eluting stents (BES) (n = 13) and underwent intravascular ultrasound evaluation immediately after the procedure and at 9-month and 5-year follow-ups. The primary endpoint was the comparison of the percentage of NIH obstruction between mid- and long-term follow-up., Results: Mean age was 59 years and 28% of patients had DM. Overall, the percentage of NIH obstruction significantly increased from 9 months to 5 years (1.3% at first follow-up vs. 4.8% at second follow-up, p = 0.002). There was no significant difference in the variation of vessel volume (Δ = -0.70 mm(3)/mm BES vs. Δ = 0.18 mm(3)/mm SES, p = 0.56), lumen volume (Δ = 0.40 mm(3)/mm BES vs. Δ = -0.05 mm(3)/mm SES, p = 0.71), and percentage of NIH obstruction (Δ = 3.0% BES vs. Δ = 3.8% SES, p = 0.55) among DES. However, diabetic patients had a marked NIH increase along the years (NIH volume at second follow-up: 10.15 mm(3) DM vs. 5.11 mm(3) non-DM, p = 0.028)., Conclusions: The present serial intravascular ultrasound assessment supports the occurrence of continuous NIH growth following different generations of DES. These findings seem to be particularly more pronounced among patients with DM., (Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
45. Optical Coherence Tomography and Fibrous Cap Characterization.
- Author
-
Chamié D, Wang Z, Bezerra H, Rollins AM, and Costa MA
- Abstract
The pathophysiology of acute coronary syndromes has long been associated with atherosclerotic plaque rupture. Inflammation, thinning, and disruption of the fibrous cap have been implicated with the final processes leading to plaque rupture, but confirmation of these mechanisms of coronary thrombosis in humans has been hampered by the lack of imaging methods with sufficient resolution to resolve fibrous cap characterization and thickness in vivo. Intravascular optical coherence tomography (OCT) provides images with micron-level axial and lateral resolution, enabling detailed visualization of micro-structural changes of the arterial wall. The present article provides an overview of the potential role of OCT in identifying and characterizing fibrous cap morphology, thickness, and inflammation in human coronary plaques.
- Published
- 2011
- Full Text
- View/download PDF
46. Optical coherence tomography endpoints in stent clinical investigations: strut coverage.
- Author
-
Tahara S, Chamié D, Baibars M, Alraies C, and Costa M
- Subjects
- Angioplasty, Balloon, Coronary adverse effects, Animals, Coronary Artery Disease pathology, Humans, Image Interpretation, Computer-Assisted, Predictive Value of Tests, Prosthesis Design, Severity of Illness Index, Thrombosis etiology, Time Factors, Treatment Outcome, Wound Healing, Angioplasty, Balloon, Coronary instrumentation, Coronary Artery Disease therapy, Drug-Eluting Stents, Thrombosis pathology, Tomography, Optical Coherence
- Abstract
Late stent thrombosis (LST) and very LST (VLST) are infrequent complications after drug-eluting stent (DES) implantation, but they carry a significant risk for patients. Delayed healing, which may be represented by incomplete stent coverage, has been observed in necropsy vessel specimens treated with DES. As a result, in vivo assessment of stent coverage, as well as stent apposition using optical coherence tomography (OCT), have been recently used as surrogate safety endpoints in clinical trials testing DES platforms. By adopting strut coverage assessed by OCT, one can assess the safety profile of the new generation of DES in preregistration studies. This article focuses on stent strut coverage as a central predictor of late DES thrombosis from the histopathological point of view, discusses the limitations of the current imaging modalities and presents the technical characteristics of OCT for the detection of neointimal coverage after stent implantation. We also review the preclinical and clinical investigations using this novel imaging modality.
- Published
- 2011
- Full Text
- View/download PDF
47. Utilization of frequency domain optical coherence tomography and fractional flow reserve to assess intermediate coronary artery stenoses: conciliating anatomic and physiologic information.
- Author
-
Stefano GT, Bezerra HG, Attizzani G, Chamié D, Mehanna E, Yamamoto H, and Costa MA
- Subjects
- Adenosine, Adult, Aged, Coronary Angiography, Coronary Stenosis pathology, Coronary Stenosis physiopathology, Female, Humans, Male, Middle Aged, Ohio, Predictive Value of Tests, Prognosis, Severity of Illness Index, Vasodilator Agents, Cardiac Catheterization statistics & numerical data, Coronary Stenosis diagnosis, Fractional Flow Reserve, Myocardial, Tomography, Optical Coherence statistics & numerical data
- Abstract
Fractional flow reserve (FFR) and intravascular imaging respectively provide hemodynamic and anatomical assessments of angiographic intermediate stenoses. Frequency domain optical coherence tomography (FD-OCT) is a promising high-resolution imaging modality, but its clinical use in determining severity of coronary disease has yet to be determined. There, we set out to determine the role of FD-OCT to complement FFR in the evaluation of intermediate coronary artery stenoses. FD-OCT was planned in 176 consecutive interventional procedures at our institution to delineate the proper use of FD-OCT in clinical practice. The decision to use other invasive assessments was at the discretion of the operator. This report describes an early series of the 14 patients who underwent FFR of 18 target stenoses in addition to FD-OCT. FD-OCT was successfully performed without complications in all cases. Fractional flow reserve was <0.80 in four patients, with minimal lumen areas and reference vessel diameters ranging from 1.03 to 3.47 mm(2) and 2.60 to 2.94 mm by FD-OCT, respectively. FD-OCT was important to rule out plaque rupture, erosion and thrombosis and to help guide decision to defer PCI in six patients with acute coronary syndrome and FFR > 0.80. FD-OCT was also valuable to guide PCI strategy in tandem lesions with an FFR < 0.80. This initial experience with FD-OCT suggests a potential complementary role of physiological and anatomical assessment to guide decision making in complex clinical scenarios. Future investigations are warranted to validate these findings and define the role of FD-OCT in assessing intermediate lesions.
- Published
- 2011
- Full Text
- View/download PDF
48. Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries).
- Author
-
Chamié D, Costa JR Jr, Abizaid A, Feres F, Staico R, Devito F, Costa RA, Abizaid A, Tanajura LF, Sousa AG, Fitzgerald PJ, Whitbourn RJ, and Sousa JE
- Subjects
- Alloys administration & dosage, Angioplasty, Balloon, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Coronary Vessels diagnostic imaging, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Registries, Alloys therapeutic use, Angioplasty, Balloon, Coronary, Coronary Angiography, Coronary Artery Disease therapy, Coronary Vessels pathology, Stents, Ultrasonography, Interventional
- Abstract
Objectives: The aim of this study was to evaluate the novel CardioMind Sparrow (CMS) stent (CardioMind, Inc., Sunnyvale, California) against the Multi-Link Pixel (MLP) stent (Guidant Corp., Santa Clara, California) for small vessel percutaneous coronary intervention (PCI)., Background: The CMS consists of a guidewire-based, self-expandable, ultra-thin nitinol stent with smaller profile and improved flexibility and deliverability. The performance of this novel device against a standard balloon-expandable stent for small vessel PCI has not been determined., Methods: Twenty-one patients were treated with the CMS and compared with 30 patients treated with MLP. Only single de novo lesions <14 mm in length, in native vessels of 2.0 to 2.5 mm were included. The primary goal was the comparison of quantitative coronary angiography lumen loss and intravascular ultrasound intimal hyperplasia (IH) formation between groups at 6 months., Results: Clinical characteristics were similar between groups. The CMS cohort had smaller vessels (2.20 +/- 0.20 mm vs. 2.43 +/- 0.16 mm, p < 0.0001) and shorter lesions (10.86 +/- 3.19 mm vs. 13.12 +/- 2.79 mm, p = 0.0091). Six-month late loss was significantly lower among CMS cohort (0.73 +/- 0.57 mm vs. 1.11 +/- 0.72 mm, p = 0.038). By intravascular ultrasound, 6-month IH volume was similar between groups (1.45 +/- 0.46 mm(3)/mm vs. 1.65 +/- 1.02 mm(3)/mm, p = 0.50). However, CMS presented a mean 13.39% expansion of its volumes, resulting in a significantly lower percentage of IH volumetric obstruction (31.94 +/- 8.19% vs. 39.90 +/- 4.72%, p = 0.0005)., Conclusions: Despite producing similar amounts of IH volume, the self-expanding CMS stent presented chronic expansion of its volumes, better accommodating the neoformed tissue and resulting in significantly lower late loss and percent of IH volumetric obstruction in comparison with the MLP stent., (Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
49. The revascular active percutaneous interventional device for coronary total occlusions study.
- Author
-
Chamié D, Abizaid A, Costa JR Jr, Feres F, Abizaid A, Staico R, Costa R, Mattos LA, Sousa AG, and Sousa JE
- Subjects
- Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary methods, Chronic Disease, Coronary Angiography, Coronary Occlusion diagnostic imaging, Feasibility Studies, Female, Humans, Male, Middle Aged, Angioplasty, Balloon, Coronary instrumentation, Coronary Occlusion therapy
- Abstract
Background: Despite the well-documented benefit of recanalization of an occluded vessel in some symptomatic patients, attempt is only performed in a minority of them. Percutaneous coronary intervention (PCI) of CTO is associated with high incidence of complications and unsuccessful procedure, mainly due to inability to cross the lesion. We sought to evaluate the efficacy and safety of the novel RVT CTO Guidewire Device (RVT-GDW, ReVascular Therapeutics, Sunnyvale, CA) in this complex scenario., Methods: The RAPID-CTO study is a non-randomized, single center, first-in-man evaluation of a new guidewire system for treatment of CTO. The RVT-GDW is a new device designed to provide enhanced penetration and positioning control for crossing CTO via: (1) an 0.014 "guidewire with a mechanically active distal end; (2) a handle attached proximally to the guidewire, with an adjustable torquer, and interfaced to (3) a non-disposable, battery-operated, control unit, that provides activation control and audio feedback during the CTO crossing procedure. Per protocol, the RVT-GDW device was only used after at least 5 min (fluoroscopy time) of attempt with commercially available conventional guidewires to cross the target lesion., Results: A total of 16 patients (16 lesions) were treated with the RVT-GDW. Mean age was 56.25 years, 56.2% were men, and 25% diabetics. The average duration of occlusion was 4.7 +/- 2.1 months. The mean vessel reference diameter was 2.76 +/- 0.31 mm and the mean lesion length was 16.64 +/- 7.70 mm (range 4.37-35.0 mm). Thirteen patients (81.2%) had "tapered stump" morphology at the proximal end of the occlusion, and a side branch was involved in 12 (75.0%). All lesions had contralateral circulation; bridging collaterals were seen in three (18.7%). Procedural success was achieved in 10 lesions (62.5%), with an average procedural time of 111.43 +/- 35.76 min. There were no major adverse cardiac events at both in-hospital and 30-day clinical follow-up., Conclusions: The first-in-man RAPID-CTO study suggests that the novel RVT-GDW device is technically feasible, safe and effective in crossing chronically occluded coronary arteries. Larger studies are warranted., ((c) 2008 Wiley-Liss, Inc.)
- Published
- 2008
- Full Text
- View/download PDF
50. Case report of lymph nodal, hepatic and splenic tuberculosis in an HIV-positive patient.
- Author
-
Barone B, Kreuzig PL, Gusmão PM, Chamié D, Bezerra S, Pinheiro P, Coscarelli P, Paiva D, Fonseca L, Marsico A, Cirigliano A, and Perez M
- Subjects
- AIDS-Related Opportunistic Infections drug therapy, Adult, Humans, Male, Mycobacterium tuberculosis isolation & purification, Treatment Outcome, Tuberculosis, Hepatic drug therapy, Tuberculosis, Lymph Node drug therapy, Tuberculosis, Splenic drug therapy, AIDS-Related Opportunistic Infections diagnosis, Antitubercular Agents therapeutic use, Tuberculosis, Hepatic diagnosis, Tuberculosis, Lymph Node diagnosis, Tuberculosis, Splenic diagnosis
- Abstract
We describe a case of a male patient, 38 years old, HIV-positive (most recent CD4 count about 259/mm(3)), with abdominal pain, nausea, vomiting, anorexia, weight loss, and vespertine high fever with chills. His hemogram showed normocytic and normochromic anemia, with a high erythrocyte sedimentation rate (ESR) and gross granulations in the neutrophils. Transaminases were normal. Bone marrow biopsy evidenced a chronic disease anemia pattern and a lack of infectious agents. Abdominal ultrasound examination showed a normal-size spleen, which exhibited heterogeneous parenchyma and multiple small hypoechoic images, together with small ascites, peripancreatic and para-aortic lymphadenopathy. These findings were confirmed by abdominal CT. The liver was normal in size, but had a hyperechoic image, which was not visualized on CT. Histopathological analysis of one of the multiple abdominal lymph nodes obtained by laparoscopic biopsy exhibited a chronic granulomatous inflammatory process, with caseous necrosis. Tissue sections were positive for BAAR (acid-alcohol-resistant bacillus), and the cultures were positive for Mycobacterium tuberculosis. Anti-tuberculosis treatment was begun, and the patient evolved with improvement of his general state, fever remission and weight gain. Splenic tuberculosis is a rare disease, occurring predominantly in patients in late stages of AIDS and/or disseminated tuberculosis. It is a difficult diagnosis, since there are no specific findings. Hence, complementary examinations, such as abdominal ultrasound/ CT, or fine needle aspiration, are usually necessary for investigation and differential diagnosis. Often, lesion regression after anti-tuberculosis regimens can be seen, and splenectomy is restricted to complicated or refractory disease.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.